Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the BioTech industry. This time, you get to discover 5 hand-picked BioTech startups advancing immunology.
Out of 954, the Global Startup Heat Map highlights 5 Top BioTech Startups advancing Immunology
The insights of this data-driven analysis are derived from the Big Data & Artificial Intelligence (AI)-powered StartUs Insights Discovery Platform, covering 2 093 000+ startups & scaleups globally. The platform gives you an exhaustive overview of emerging technologies & relevant startups within a specific field in just a few clicks.
The Global Startup Heat Map below reveals the distribution of the 954 exemplary startups & scaleups we analyzed for this research. Further, it highlights 5 BioTech startups that we hand-picked based on criteria such as founding year, location, funding raised, and more. You get to explore the solutions of these 5 startups & scaleups in this report. For insights on the other 949 BioTech startups advancing immunology, get in touch with us.
Kira Biotech develops Immunomodulatory Compounds
Founding Year: 2019
Location: Brisbane, Australia
Funding: USD 20 M
Partner to develop treats against Autoimmune Diseases
Australian startup Kira Biotech develops novel immunomodulatory compounds for the treatment of immune system disorders. The startup’s lead candidate, KB312 is a selective, immune-cell depleting monoclonal antibody. This antibody targets activated immune cells and restores homeostasis through induction of immune tolerance. Immunotherapeutics are highly expensive and are unaffordable for patients in many regions of the world. Kira Biotech’s immunomodulatory compounds offer an affordable and effective cure for autoimmune diseases.
Aditxt offers Immune System Profiling
Founding Year: 2017
Location: Mountain View, USA
Funding: USD 22,4 M
Reach out for working with Immunosuppressants
US-based startup Aditxt develops novel nucleic acid-based technology to treat immune system-related diseases. The startup’s AditxtScore technology platform provides immune system profiling for early warning signs. Additionally, the startup’s AditxtReprogramming platform uses a proprietary technology that mimics natural self-tolerance. This technology finds applications in organ transplantation, skin grafting, autoimmune diseases, and allergies. The startup’s solutions prevent complications that generally arise from the use of immunosuppressants.
Alderaan Biotechnology modulates Cancer Treatment
Founding Year: 2017
Location: France, Paris
Funding: EUR 20 M
Collaborate for Immuno-Oncotherapy
French startup Alderaan Biotechnology develops novel cancer treatment therapies that leverage immune system cells. The startup’s solution is based on Treg depletion using CD25-specific, IL2, and effector T-cell sparing antibodies. The monoclonal antibodies that recognize CD25 on Treg cells allow their efficient depletion from the tumor microenvironment without impacting the effector T cells involved in tumor destruction. The treatment also uses specific monoclonal antibodies to boost the rate of cancer cell destruction in the tumor by hyper-activating particular positive natural killer (NK) cells. The startup’s cancer treatment therapies activate patients’ innate immune cells to combat cancer tumor microenvironments.
Ahead Therapeutics treats Autoimmune Diseases
Founding Year: 2017
Location: Barcelona, Spain
Funding: EUR 71 400
Partner for Cancer Treatment
Spanish startup Ahead Therapeutics develops a nanotechnology-based pharmacological platform to treat autoimmune diseases. The startup’s technology leverages the bio-mimicking efferocytosis process in which, dendritic cells (DCs) engulf and remove apoptotic cells from the body. The platform uses liposomes of certain particle sizes to encapsulate a specific autoantigen, depending on the illness being treated. The barriers to autoimmune disease lie in the risks of secondary effects, toxicity, and high costs of treatment. Ahead Therapeutics’ solution enables the development of efficient and economical treatments for autoimmune diseases.
Gracell advances CAR-T Cell Therapies
Founding Year: 2017
Location: Jiuquan, China
Funding: USD 185 M
Work with Gracell to advance Cell Therapy
Chinese scaleup Gracell specializes in chimeric antigen receptor (CAR)-T cell therapies. Its autologous CAR-T platform activates patients’ T cells using CD3 or CD28 antibodies. The activated T cells are transduced by virus vectors to express one or more CAR’s and subsequently expanded ex-vivo before re-administration. Additionally, the startup’s proprietary TruUCAR platform generates high-quality allogeneic CAR-T therapies which function as a standalone therapy to eradicate cancer with a single infusion. Moreover, Gracell’s solutions overcome one of the key challenges to cancer therapies by reducing manufacturing times from weeks to days.
Discover more BioTech Startups
BioTech startups such as the examples highlighted in this report focus on biochemistry, genetics, and cell biology. While all of these technologies play a major role in advancing the industry, they only represent the tip of the iceberg. To explore BioTech technologies in more detail, simply let us look into your areas of interest. For a more general overview, download our free BioTech Innovation Report to save your time and improve strategic decision-making.
